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Abstract
Background: This study aimed to explore the role of patient’s characteristic and haematological factors as
predictive on the maturation of arteriovenous fistulae in patients who underwent vascular access surgery at the
Royal Infirmary of Edinburgh.
Methods: Retrospective data from 300 patients who had undergone fistula creation between February 2007 and
October 2010 was examined. A predictive logistic regression model was developed using the backward stepwise
procedure. Model performance, discrimination and calibration, was assessed using the receiver operating
characteristics (ROC) curve and Hosmer and Lemeshow goodness of fit test.
Results: Three variables were identified which independently influenced fistula maturation. Males were twice as
likely to undergo fistula maturation, compared to that of females (odds ratio (OR) 0.514; 95% confidence interval (CI)
0.308–0.857), patients with no evidence of peripheral vascular disease (PVD) were three times more likely to mature
their fistula (OR 3.140; 95% CI 1.596–6.177) and a pre-operative vein diameter > 2.5 mm resulted in a fivefold
increase in fistula maturation compared to a vein size less than 2.5 mm (OR 4.532; 95% CI 2.063–9.958). The model
for fistula maturation had fair discrimination as indicated by the area under the ROC curve (0.68; 95% CI 0.615–0.
738) but good calibration indicated by Hosmer and Lemeshow test (p = 0.79).
Conclusion: Gender, PVD and vein size are independent predictors of arteriovenous fistula maturation. The clinical
utility of these risk equation in the maturation of arteriovenous fistulae requires further validation in the newly
treated patients.
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Background
Chronic kidney disease (CKD) is a critical condition with
considerable public health implications. It affects a sig-
nificant proportion of the general population and, when
progressive, has an increasing influence on morbidity
and mortality. In the USA, it is reported that 10% (more
than 20 million adults) are affected with CKD [1]. In the
UK, the prevalence of stage 3–5 CKD is 1.7 million
adults [2] with an annual incidence of stage 5 CKD of
100 per million of the population [3]. Once a patient
reaches end-stage kidney disease, their quality of life
becomes poor and the life expectancy is considerably
shortened [4]. According to the United States Renal
Data System [5], more than 87,000 people die from
causes related to kidney failure each year.
Through the provision of renal replacement therapy,
survival and quality of life of the patients can be mark-
edly improved [6]. The efficiency of haemodialysis treat-
ment relies on a functional status of vascular access, and
complications here represent the main factor that deter-
mines a rise in the morbidity among haemodialysis
patients and consequently, a rise in the healthcare
expenses [7]. In the UK, renal replacement therapy uti-
lizes up to 2% of its financial resources [8]. To ensure
that the dialysis therapy can be efficiently undertaken, all
patients have to have a fully developed fistula appropriate
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for cannulation. The percentage of arteriovenous fistulae
(AVF) that fail to mature for haemodialysis is 28–53% [9].
The dialysis therapy is often postponed for up to 6 months
or more to allow extra time for the fistula to develop; if this
does not happen, the AVF is declared as ‘failed to mature’.
The development process of AVF is complicated, and it is
difficult to settle on the precise length of time it requires to
mature [10]. Several researchers [11–16] have recom-
mended a number of pre-surgical principles relying on in-
vasive and non-invasive procedures; however, factors, such
as cost, time and complexity, hinder the widespread appli-
cation of these principles.
It may be possible to improve the end results of vascu-
lar access by gaining a more comprehensive picture
about the various factors involved in the maturation of
fistulae. This could then in turn provide important infor-
mation during the pre-surgical evaluation that surgeons
can base their decisions on. Independent predictive
factors may be beneficial in anticipating successful fistula
maturation without the use of invasive tests, and this
could be cost-effective. The objective of the study was to
assess factors which are important in the successful matur-
ation of AVF. These were used to formulate a simple and
economical prognostic model on the maturation of AVF.
Methods
Research design
This is a single-centre exploratory study that involved
the collection of retrospective data from the Royal
Infirmary of Edinburgh and identification of those
independent predictors for a predictive model of fistula
maturation. A favourable ethical opinion was obtained
from the NHS Lothian ethics committee and Queen
Margaret University ethics committee for the study.
Using the retrospective clinical database of patients
with ESRD, we identified 300 patients between February
2007 and October 2010 who had undergone vascular
access surgery for first-time AVF creation. Patients who
underwent a repeat AVF creation (second and further
fistula creations) were not included in this study. Pur-
posive sampling technique was used for patient’s recruit-
ment. Study was performed systematically in different
steps from identification, screening, recruitment, data
collection of potential participants and finally data ana-
lysis by using appropriate statistical test (Fig. 1).
A retrospective case note review was performed on all
patients identified from the hospital vascular access
database as having undergone construction of AVF. The
medical case files of the patients who had undergone
fistula surgery between 2007 and 2010 were retrieved
from the medical records (Proton® software and Apex®
software) at the Royal Infirmary Edinburgh. At the be-
ginning, all potential participants’ records were screened
comprehensively. From the data, reports of patients were
developed from the pre-operative assessment papers and
the clinical results of their operation obtained from the
clinical records and follow-up case notes.
The details of patient’s factor and blood markers were
explored by complete review of the patient’s inpatient
and outpatient medical record (containing all informa-
tion pertaining to medical and surgical consultations
and all previous hospital admissions and management)
via an electronic database. All the data was entered into
an Excel spreadsheet (Microsoft, USA).
The patient record including age, gender and risk fac-
tors; peripheral vascular disease (PVD); diabetes mellitus
(DM); hypertension (HTN); smoking (ever versus never);
and dialysis (ever versus never). Patients were defined as
obese when their body mass index was > 30, consistent
with the World Health Organization classification [17].
Fistula characteristics that were ascertained included
fistula type and its location (right or left). Clinically
important biomedical factors including estimated glom-
erular filtration rate (eGFR); creatinine; blood urea;
serum potassium (K); sodium (Na); calcium (Ca); bicar-
bonate (HCO3); prothrombin time (PT); international
normalization ratio (INR); high-density lipoprotein
(HDL); triglyceride (TG); total cholesterol (TC); and vein
diameter were also included in the analysis. Duplex
investigation of the veins was performed to measure the
diameter of arm veins according to a standard protocol
by vascular scientists in the vascular clinic of Royal
Infirmary Edinburgh. All procedures such as general
physical examination consisted of inspection and palpa-
tion of the vessels of the upper arm and forearm and
measurement of brachial artery blood pressure. Subse-
quently, height and weight details were recorded in
order to calculate the BMI values and blood samples
were obtained by the regular NHS staff. PVD was identi-
fied through a physical examination and by comparing
the blood pressure in the arm and ankle. Ankle-brachial
pressure index (ABPI) ≤ 0.90 reliably identifies 95% of
symptomatic arteriogram-positive PVD individuals and
almost 100% of healthy controls [18].
Outcome definition
Maturation was defined as the ability to provide on-
going functional haemodialysis at the sixth week [19, 20]
from the access procedure. An experienced dialysis spe-
cialist nurse determined when the fistula was ready for
an attempt at cannulation and then attempted initial
cannulation of the fistula; if unsuccessful, the fistula then
was evaluated by the vascular surgeon at the Royal
Infirmary of Edinburgh.
Statistical analysis
Statistical analysis was performed using SPSS (IBM SPSS
Statistics 20.0). Data was expressed as mean, standard
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deviation (SD) and 95% confidence interval (CI) or as
proportions. The association between the independent
factors and outcome, i.e. mature fistula, was assessed
initially employing univariable logistic regression, and
following this, a multivariable model was produced
utilizing backward stepwise logistic regression with those
variables found to be significant in the univariable
regression at p < 0.25. The odds ratios and associated
95% confidence intervals for variables in the final model
were reported. The significance level for the multivari-
able model was set at p < 0.05. Multicollinearity in the
model was investigated to assess the relationship
between the independent factors. We evaluated the
calibration and discrimination performance of the
model. For the calibration, the Hosmer-Lemeshow test
was employed to investigate how well the predicted
probabilities agreed with the observed probabilities.
Discrimination, which refers to the ability of a model to
distinguish between the maturation and immaturation of
the AVF, was quantified using the ROC curve. The ROC
curve plots the sensitivity (true positive rate) against
1—specificity (false positive rate) for consecutive cut-offs
for the probability of an outcome [21].
Results
Retrospective data was obtained for 300 patients who
underwent vascular access surgery. Ages ranged from 19
to 87 years, with a mean age of 60.5 (16) years. Success-
ful maturation of the AVF was achieved in 168 (56%) pa-
tients as assessed by dialysis specialist nurses.
Univariable associations
AVF characteristics and univariable analysis of clinical
variables for the prediction of maturation of fistula are
shown in Table 1. Univariable analysis found nine vari-
ables to be associated with maturation of AVF: gender,
side of arm, type of fistulae, PVD, diabetes, SBP, INR,
TG and vein size. In addition to the above variables, a
further two statistically non-significant variables, i.e. dia-
lysis [22, 23] (ever versus never) and eGFR [24], were
added to the model due to their possible clinical associ-
ation with the maturation of AVF as suggested by the
vascular surgeons.
Multivariable associations
Three variables were identified which were independ-
ently associated with fistula maturation using
Fig. 1 Flow diagram showing steps of the study
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Table 1 Univariable analysis of independent factors to maturation of AVF
Clinical characteristics Mature AVF % Total % Crude OR (95% CI) p value
Age 0.45
> 50 years 57.2 76.3
≤ 50 years 52.1 23.7 0.814 (0.477–1.389)
Gender 0.049*
Male 60 66.7
Female 48 33.3 0.615 (0.379–0.998)
Arm 0.129*
Left 53.4 73.7
Right 63.3 26.3 1.505 (0.887–2.553)
Fistula 0.115*
BC 60.1 62.7
RC 51.9 27 0.715 (0.423–1.208)
BB 41.9 10.3 0.479 (0.222–1.036)
Surgeons 0.788
Surgeon A 56.4 68.0
Surgeon B 56 25.0 0.985 (0.578–1.679)
Surgeon C 71.4 2.3 1.935 (0.367–10.206)
Surgeon D 40 1.7 0.516 (0.084–3.154)
Surgeon E 44.4 3 0.619 (0.162–2.373)
PVD 0.001*
Yes 33.3 16
No 60.3 84 3.04 (1.585–5.829)
DM 0.102*
Yes 50 38
No 59.7 62 1.48 (0.925–2.367)
Smoker 0.49
Yes 61 13.7
No 55.2 86.3 0.789 (0.402–1.547)
HTN 0.406
Yes 57.3 78
No 51.5 22 0.793 (0.458–1.371)
Dialysis 0.513
Yes 53.6 37.3
No 57.4 62.7 1.17 (0.731–1.873)
K+ (mmol/L) 0.948
Normal 56.2 54.3
Abnormal 55.8 45.7 1.015 (0.642–1.605)
Na+ (mmol/L) 0.439
Normal 55.1 85.3
Abnormal 61.4 14.7 1.295 (0.673–2.494)
Ca++ (mmol/L) 0.525
≤ 2.5 56.7 87
> 2.5 51.3 13 0.804 (0.41–1.577)
HCO3 (mmol/L) 0.743
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Table 1 Univariable analysis of independent factors to maturation of AVF (Continued)
Clinical characteristics Mature AVF % Total % Crude OR (95% CI) p value
≤ 23 57 45
> 23 55.2 55 0.926 (0.586–1.465)
Creatinine (mmol/L) 0.676
> 400 57.5 44.7
> 120 ≤ 400 55.2 54.3 0.913 (0.576–1.447)
≤ 120 33.3 1 0.37 (0.033–4.182)
Urea (mmol/L) 0.949
> 15 55.3 65.7
> 6.6–≤ 15 57.1 18.7 1.076 (0.591–1.960)
≤ 6.6 57.4 15.7 1.09 (0.73–2.073)
eGFR (ml/min/1.73m2) 0.459
≤ 15 57.4 64.6
> 15 52.9 35.4 0.834 (0.516–1.349)
SBP (mm of Hg) 0.101*
≤ 130 51.6 53
> 130 48.4 47 1.468 (0.927–2.325)
DBP (mm of Hg) 0.786
≤ 85 56.3 90.7
> 85 53.6 9.3 0.897 (0.411–1.958)
BMI (kg/m2) 0.563
≤ 30 55 73.3
> 30 58.8 26.7 1.165 (0.694–1.957)
PT (s) 0.413
≤ 13.4 56.9 86.6
> 13.5 50 13.4 0.757 (0.389–1.474)
INR (ratio) 0.140*
≤ 1.2 57.6 88
> 1.2 44.4 12 0.589 (0.292–1.189)
TC (mmol/L) 0.24*
≤ 5 57.9 76
> 5 50 24 1.294 (0.804–2.084)
TG (mmol/L) 0.289
≤ 2.1 53.7 63.3
> 2.1 60 36.7 0.773 (0.48–1.244)
HDL (mmol/L) 0.874
≤ 1.1 55.6 51
> 1.1 56.5 49 1.037 (0.658–1.637)
Vein size (mm) < 0.001*
≤ 2.5 26.3 12.6
> 2.5 60.3 87.4 4.254 (1.983–9.126)
Independent patient factors and blood markers that underwent in univariate analysis and their association with the maturation of AVF. Data
values are expressed as value (%), odds ratio (OR), confidence interval (CI) and level of significance (p)
BC brachiocephalic, RC radiocephalic, BB bicarbonate, PVD peripheral vascular disease, DM diabetes mellitus, HTN hypertension, K potassium, Na
sodium, Ca calcium, HCO3 bicarbonate, e-GFR estimated glomerular filtration rate, SBP systolic blood pressure, DBP diastolic blood pressure, BMI
body mass index, PT prothrombin time, INR international normalization ratio, TC total cholesterol, TG triglyceride, HDL high density lipoprotein
*Significant variables having p value < 0.25
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multivariable logistic regression analysis (Table 2). Males
were twice as likely to undergo fistula maturation,
compared to females (OR 0.514; 95% CI 0.308–0.857;
p = 0.011) with patients who had no evidence of PVD
being three times more likely to mature their fistula
(OR 3.140; 95% CI 1.596–6.177; p < 0.001) and those
with a pre-operative vein diameter greater than
2.5 mm [25, 26] resulting in a fivefold increase in fis-
tula maturation compared to a vein size less than
2.5 mm (OR 4.532; 95% CI 2.063–9.958; p < 0.001).
No multicollinearity was observed between the inde-
pendent factors.
The overall risk score for each patient was estimated
by summing the scores of each significant independent
variable. Using the prediction model, the following
prognostic equation was developed:
Risk score − logoddsð Þ ¼ β0 þ β1X1 þ β2X2 þ……
þ βnXn
where β0 is the intercept, β1 till βn are the regression
coefficients and X1 to Xn are independent variables.
Risk score − log odds of failure of AVF maturationð Þ
¼ 00:182þ −0:666 genderð Þ þ 1:144 PVDð Þ
þ 1:511 vein sizeð Þ
where all variables are coded 0 for no or 1 for yes. The
value − 0.182 is called the intercept, and the other num-
bers are the estimated regression coefficients for the pre-
dictors, which indicate their mutually adjusted relative
contribution to the outcome risk.
The performance of the final prognostic model assessed
in terms of calibration using Hosmer-Lemeshow test was
not significant (p = 0.79). This suggests that there was no
statistically significant difference between predicted and
observed outcomes. The area under the ROC curve for
prediction of maturation of fistula was 0.68 (95% bias-
corrected CI 0.615, 0.738), which indicates fair [27]
discrimination (Fig. 2).
Discussion
The results of this study identify three clinical factors,
each of which was independently associated with matur-
ation of AVF: male gender, PVD and vein diameter. AVF
successfully matured in 168 patients, accounting for 56%
of the total number of patients. Similar results have been
obtained by Feldman et al. [28], with 55.5% out of a total
of 348 patients exhibiting successful AVF maturation.
The study result showed a gender difference, mature
rates of 60% for men and of 48% for women. Miller et
al. [29] found Ithat the AVF maturation is more
successful in men than in women. Similar results were
obtained by Gibbons [30] and Iyem [31]. In our study,
males were twice as likely to undergo fistula maturation,
compared to that of females; the most rational explan-
ation for this difference is the smaller size of vessels in
women. Some studies also found female gender to be
associated with immature fistula [12, 13, 15, 32]. How-
ever, there are also studies that did not show a gender
difference. Jennings et al. [26] involved the creation of
AVFs on 114 participants and did not observe any
gender difference in the maturation of AVF [33, 34].
Out of 300 patients, 38% were diabetic and 16% had
clinical evidence of PVD. In a number of studies, it has
been reported that more than 50% of North American
dialysis patients had diabetes, and approximately one
Table 2 Multivariable predictors of AVF maturation
Predictors of AVF maturation Test statistics and associated degree of freedom Adjusted OR (95% CI) p value
Gender (male) χ2(1) = 3.896, p = 0.048 0.514 (0.308–0.857) 0.011
PVD (no) χ2(1) = 11.91, p = 0.001 3.140 (1.596–6.177) < 0.001
V. size (> 2.5) χ2(1) = 15.56, p < 0.001 4.532 (2.063–9.958) < 0.001
Model summary
−2 log-likelihood
Cox and Snell R2 Nagelkerke R2
378.714 0.104 0.139
Fig. 2 Receiver operating curve analysis for prognostic
model performance
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third had PVD [35–37]. In our study, fistula maturation
was 59.7% in a group with no history of PVD and 33.3
in patients with PVD. This emerged as one of the pre-
dictive factors in the maturation of fistulae in the multi-
variable analysis. Patients with no evidence of PVD were
three times more likely to mature their fistula. Our data
is consistent with other studies in which PVD was asso-
ciated with AVF failure [38, 39]. Chan et al. conducted a
retrospective cohort analysis using 1486 patients’ data
[40]. It was revealed that patients who suffer from PVD
are more likely to experience non-maturation of AVF
(OR 2.78, 95% CI 1.01–7.63, p = 0.047). Fistula failure is
consistent with the underlying need for adequate arterial
vessels, which deteriorate with the normal aging process
and are damaged by concurrent disease; this finding is
supported by other studies [11, 41].
Our data are consistent with other studies in which
vein size was associated with successful maturation of
fistulae. Mendes et al. reported that if the diameter of
the cephalic veins exceeds 2 mm, there is a 76% success
rate of functional dialysis access, whereas if the diameter
is less than 2 mm, there is only a 16% success rate [14].
In this study, a pre-operative vein diameter greater than
2.5 mm resulted in a fivefold increase in fistula matur-
ation compared to a vein size less than 2.5 mm. Our
data is consistent with other studies in which vein size is
associated with successful fistula maturation [41, 42].
The cut-off value identified by Brimble et al. was
2.6 mm; however, only women exhibited a substantial
discrepancy between AVF success and failure with re-
gard to vein diameter [43]. In contrast, Wong et al. did
not observe any discrepancies between AVF success and
failure in the mean vein diameter at the wrist but indi-
cated AVF failure in all cases where the vein diameter
was below 1.6 mm [44].
This study hypothesized that blood and patient factors
could be used to stratify risk of self-report of maturation
of AVF. In brief, using the development dataset of 300
subjects, we identified three variables associated with
maturation of fistula: gender, PVD and vein size. The
performance of the developed model in this study was
assessed by discrimination and calibration of the model.
The area under the ROC curve for a prognostic model is
classically between 0.6 and 0.85 [45]. In our study, ROC
curve was primarily designed for prognostic models, ra-
ther for diagnostic models. ROC curve was 0.68 in the
development model and 0.59 in the validation stage,
meaning that the model had limited capacity to correctly
distinguish between mature and immature fistulae.
The present study has a number of limitations. The
connection between artery diameter and blood inflow
rate was emphasized by a number of studies [42, 46, 47].
However, we did not included artery diameter and arter-
ial blood flow in our study due to the unavailability of
retrospective data. Another limitation were the duplex
measurements of the vein diameter and measurements
of vessel diameter carried out by vascular scientists who
had a great deal of experience and were familiar with the
procedure. The objective of the scientist was to carry
out the measurements in spite of the differences
between pre-surgery examination and the actual inter-
vention. However, there were few staff changes during
the 5 years when the fistulae were constructed. As
argued by Pisoni et al. [48], it is important to take into
consideration non-measurable elements, such as meas-
urement techniques and principles of care, apart from
ample case-mix adaptations highlighted by other studies.
Conclusion
A preoperative, clinical prediction model to determine
fistulae that are likely to mature was created. It was
found to be simple and easily reproducible and applied
to predictive risk categories. Gender, PVD and vein size
are useful predictors of arteriovenous fistula maturation.
The clinical utility of these risk categories in the matur-
ation of arteriovenous fistula requires further validation
in the newly treated patients.
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